CancerCARMA-BROSNCT04151342
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
An observational study of Cancer and Malignancies Multiple, run by University Health Network, Toronto at 27 sites in Canada.
Trial summary
This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Malignancies Multiple, Malignant Solid Tumor
- What is being tested?
- Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. and Patient-reported outcomes (PROs)
- How many people
- 5,500 participants
- Where
- 27 sitesCanada
- Study dates
- 17 Jan 2020to Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cancer patients living and deceased who have/had a histologically confirmed rare molecular alteration in their tumours, such as but not limited to ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
Who may be able to join
- Patients ≥ 18 years at cancer diagnosis
- Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
- Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction [PCR] based next generation sequencing [NGS], immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], liquid biopsy)
- Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment
Who cannot join
- Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent
Trial locations and contacts
27 sites in 1 country. Contact the study team or a site near you to ask about taking part.
27 sites in 1 country
Canada27 sites, 27 recruiting
- Recruiting
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Parneet Cheema, MD, FRCPC
- Recruiting
Tom Baker Cancer Centre - University of Calgary - Alberta Health Services
Calgary, Alberta
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Vishal Navani, MA (Oxon), MBBS, MRCP, FRACP
- Not yet recruiting
Cross Cancer Institute, University of Alberta - Alberta Health Services
Edmonton, Alberta
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Quincy Siu-Chung Chu, MD, FRCPC
- Recruiting
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Luisa Galvis-Gomez, MD
- Recruiting
Health Sciences North
Greater Sudbury, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Abhenil Mittal, MD
- Recruiting
Queen Elizabeth II (QEII) Health Sciences Centre
Halifax, Nova Scotia
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Stephanie Snow, MD, FRCPC
- Recruiting
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Rosalyn Juergens, MD, PhD
- Recruiting
Kingston Health Sciences Centre (KHSC)
Kingston, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Sofia Genta, MD
- Recruiting
Lawson Health Research Institute - London Health Sciences Centre
London, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Sara Kuruvilla, MD, FRCPC
- Recruiting
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Normand Blais, MD, MSc
- Recruiting
Hôpital du Sacré-Coeur-de-Montréal (HSCM)
Montreal, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Kevin Jao, MD, PhD
- Recruiting
Jewish General Hospital
Montreal, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Jason Agulnik, MD
- Not yet recruiting
McGill University Health Centre
Montreal, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Jonathan Spicer, MD, PhD
- Not yet recruiting
St. Mary's Hospital Center
Montreal, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Nicholas Meti, MD
- Recruiting
Ottawa Hospital Cancer Centre
Ottawa, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Paul Wheatley-Price, MBChB, FRCP(UK), MD
- Not yet recruiting
Centre hospitalier de l'université de Québec - Université Laval
Québec, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Nicolas Marcoux, MD, FRCPC
- Not yet recruiting
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Philippe Joubert, MD, PhD
- Not yet recruiting
Allan Blair Cancer Centre
Regina, Saskatchewan
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Ayesha Bashir, MD, FRCPC
- Not yet recruiting
Saskatoon Cancer Centre
Saskatoon, Saskatchewan
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Sunil Yadav, MD
- Recruiting
Centre hospitalier universitaire de Sherbrooke (CHUS)
Sherbrooke, Quebec
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Nicole Bouchard, MD
- Not yet recruiting
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Elizabeth Faour, MD
- Not yet recruiting
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Olexiy Aseyev, MD
- Recruiting
Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN)
Toronto, Ontario, M5G 2M9
Faisal Al-Agha, BSc, 416-946-4501 ext. 3428, faisal.al-agha@uhn.ca
Geoffrey Liu, MD, MSc
- Recruiting
Mount Sinai Hospital
Toronto, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Ronald Burkes, MD, FRCPC
- Recruiting
Sunnybrook Research Institute - Sunnybrook Health Sciences Centre
Toronto, Ontario
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Ines Menjak, MD, FRCPC
- Recruiting
BC Cancer
Vancouver, British Columbia
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Cheryl Ho, MD, FRCPC
- Recruiting
CancerCare Manitoba/University of Manitoba
Winnipeg, Manitoba
Roula Raptis, MSc, Roula.Raptis@unityhealth.to
Shantanu Banerji, MD, FRCPC
About this study
This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.
Read the detailed description
Molecular heterogeneity in cancer tumours make it a complex disease to manage and treat. However, there have been significant advancements made in the detection of molecular alterations and we are able to now define distinct disease subtypes which permit targeted selection of therapies, thus optimizing treatment responses for patients and improving their survival.
With CARMA-BROS we will address the objectives that follow.
Primary Objectives:
- To create a cohort of patients through which to better understand the natural history of disease in Canadian cancer patients with tumours that have been molecularly subtyped and identified to have rare molecular alterations.
- To compare the natural history, stage distribution, treatment outcomes such as treatment effectiveness (composite of disease progression or death) and treatment toxicities across different patients with different molecular alterations, receiving different lines and types of therapy. Secondary Objectives:
- To determine the incidence, time to development, prevalence, and outcomes of patients with specific patterns of spread, such as brain metastases compared to those without, by different therapies and by molecular alterations.
- To better understand real-world treatment patterns of rare molecular alterations in the Canadian context, across geographic or other factors, and how treatment patterns evolve over time and as new therapies become available, how patients are investigated and how targeted and other biomarkers are used as part of clinical practice in these patients.
- To assess quality of life in patients with rare molecular alterations across different stages, lines and types of therapy.
- To perform exploratory health economic evaluations focused on the costs and benefits of managing patients with rare molecular alterations.
- To perform biomarker analyses, where appropriate, to improve our understanding of these rare molecular alterations.
- Conditions
- Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration
- Being tested
- Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
- Keywords
- observational study, cancer, cancer therapies, molecular alterations, real-world evidence, real-world data, tyrosine kinase inhibitors, ambispective, ras GTPase inhibitors
- Medical subject headings
- Neoplasms, Neoplasms, Second Primary, Congenital Abnormalities
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.Drug
Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
Patient-reported outcomes (PROs)Other
Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
| Study group | Role | What they receive |
|---|---|---|
| Prospective | Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada. Receives: Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.; Other: Patient-reported outcomes (PROs) | |
| Retrospective | Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada. Receives: Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | |
| Comparator group | All cancer patients without rare molecular alterations in their solid tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite of Progression Free Survival [PFS] or Overall Survival [OS]
Composite of disease progression or death
Measured: From the start date of cancer therapy until the date of first documented progression or date of death (any cause), assessed up to 120 months
Secondary outcomes (4)
Brain metastasis/other metastatic tumours
Confirmed through imaging (MRI, CT) or determined through treatment indication(s), for example, brain radiation therapy (surrogate for presence of brain metastasis)
Measured: From the start date of cancer therapy until the date of first documented brain/other metastasis, assessed up to 120 months
EORTC quality of life questionnaires (QLQ) - cancer patient-reported health related quality of life
Prospectively enrolled participants will complete the following health related quality of life surveys: EORTC QLQ-C30 (core) and EORTC QLQ-LC13 (disease specific module)
Measured: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
EQ-5D-5L - patient-reported health related quality of life measure
Prospectively enrolled participants will complete the health related quality of life survey: EQ-5D-5L.
Measured: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
Patient-reported economic impact
Prospectively enrolled participants will complete the "Work Productivity and Activity Impairment Questionnaire: General Health" (WPAI:GH) and other economic impact questions that capture indirect costs incurred as a result of their disease.
Measured: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2019
- Study start17 Jan 2020
- Primary completionDec 2029 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 5,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, Nuvation Bio Inc., IQVIA Solutions Canada Inc.
- Responsible party
- Sponsor
- Investigators
- Geoffrey Liu, MD, MSc, Principal investigator, Princess Margaret Cancer Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04151342
- Sponsor's protocol ID
- CARMA-BROS
- Other IDs
- 18-5902, 1632
- Acronym
- CARMA-BROS
- Status last verified
- Nov 2025
- First submitted
- 29 Oct 2019
- Last updated
- 3 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
- ClinicalTrials.gov ID
- NCT04151342
- Acronym / sponsor ID
- CARMA-BROS / CARMA-BROS
- Conditions
- Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration
- Keywords
- observational study, cancer, cancer therapies, molecular alterations, real-world evidence, real-world data, tyrosine kinase inhibitors, ambispective
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,500 participants (estimated)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Collaborators
- Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, Nuvation Bio Inc., IQVIA Solutions Canada Inc.
- Study start
- 17 Jan 2020 (actual)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 5 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.
Detailed description
Molecular heterogeneity in cancer tumours make it a complex disease to manage and treat. However, there have been significant advancements made in the detection of molecular alterations and we are able to now define distinct disease subtypes which permit targeted selection of therapies, thus optimizing treatment responses for patients and improving their survival.
With CARMA-BROS we will address the objectives that follow.
Primary Objectives:
- To create a cohort of patients through which to better understand the natural history of disease in Canadian cancer patients with tumours that have been molecularly subtyped and identified to have rare molecular alterations.
- To compare the natural history, stage distribution, treatment outcomes such as treatment effectiveness (composite of disease progression or death) and treatment toxicities across different patients with different molecular alterations, receiving different lines and types of therapy. Secondary Objectives:
- To determine the incidence, time to development, prevalence, and outcomes of patients with specific patterns of spread, such as brain metastases compared to those without, by different therapies and by molecular alterations.
- To better understand real-world treatment patterns of rare molecular alterations in the Canadian context, across geographic or other factors, and how treatment patterns evolve over time and as new therapies become available, how patients are investigated and how targeted and other biomarkers are used as part of clinical practice in these patients.
- To assess quality of life in patients with rare molecular alterations across different stages, lines and types of therapy.
- To perform exploratory health economic evaluations focused on the costs and benefits of managing patients with rare molecular alterations.
- To perform biomarker analyses, where appropriate, to improve our understanding of these rare molecular alterations.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Prospective | – | Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Other: Patient-reported outcomes (PROs)Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada. |
| Retrospective | – | Drug: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada. |
| Comparator group | – | –All cancer patients without rare molecular alterations in their solid tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cancer patients living and deceased who have/had a histologically confirmed rare molecular alteration in their tumours, such as but not limited to ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
Key inclusion criteria (4 listed)
- Patients ≥ 18 years at cancer diagnosis
- Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
- Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction [PCR] based next generation sequencing [NGS], immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], liquid biopsy)
- Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment
Key exclusion criteria (1 listed)
- Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment. | Drug | Prospective, Retrospective |
| Patient-reported outcomes (PROs)Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed. | Other | Prospective |
Primary outcome
Composite of Progression Free Survival [PFS] or Overall Survival [OS]
Time frame: From the start date of cancer therapy until the date of first documented progression or date of death (any cause), assessed up to 120 months
Composite of disease progression or death
4 secondary outcomes
Brain metastasis/other metastatic tumours
Time frame: From the start date of cancer therapy until the date of first documented brain/other metastasis, assessed up to 120 months
EORTC quality of life questionnaires (QLQ) - cancer patient-reported health related quality of life
Time frame: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
EQ-5D-5L - patient-reported health related quality of life measure
Time frame: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
Patient-reported economic impact
Time frame: Baseline and serial changes every 3 months, including whenever there is a change in treatment, up to 120 months (the duration of this study)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Geoffrey Liu, MD, MSc principal investigator
Princess Margaret Cancer Centre
27 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Malignancies Multiple, run by University Health Network, Toronto at 27 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Faisal Al-Agha, BSc (416-946-4501, faisal.al-agha@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite of Progression Free Survival [PFS] or Overall Survival [OS] (time frame: From the start date of cancer therapy until the date of first documented progression or date of death (any cause), assessed up to 120 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.